Curis | CRIS - Selling And Administration Expenses


Curis reported $2.96M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 424K 23K Jun/2026
Amgen USD 1.68B 40M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bayer EUR 4.02B 53M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
CSL USD 1.23B 498M Dec/2025
Curis USD 2.96M 1.62M Mar/2026
Eli Lilly USD 3.12B 305M Sep/2026
Exelixis USD 154.56M 6.93M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
Takeda JPY 271.71B 14.8B Sep/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Verastem USD 22.3M 2.14M Mar/2026